FDA Issues an Early Alert on Edwards' Commander M Delivery System After Balloons Burst. One Death Is Reported.
The Oct. 15 alert names four lots of the system used to deliver the SAPIEN M3 transcatheter mitral valve and cites three reports of balloons bursting during inflation. Facilities are told not to use the lots and to remove them from inventory.
On Oct. 15, the Food and Drug Administration (FDA) posted an early alert about the Commander M delivery system, used with the SAPIEN M3 transcatheter mitral valve replacement system made by Edwards Lifesciences. Edwards has received three reports of balloons bursting during inflation and, as of Oct. 5, had reported one death and one serious injury associated with the issue.
The FDA's device center uses early alerts to notify the public of a potentially high-risk device issue while it reviews a company's corrective action. The page does not give a recall classification, and the FDA says it will update it as significant new information becomes available.
Which lots and what can happen
Four lots are named: 67718561, 67804014, 67887043 and 67887044. Units with other lot numbers are not affected and can continue to be used, according to the alert. A burst balloon can cause embolism and can make it impossible to retrieve the device through the guide sheath, which may require additional intervention, including surgery. The alert notes that because these patients are deemed unsuitable for surgery, those interventions carry a high risk of serious harm, including death.
The patient group is narrow by design. When the FDA approved the SAPIEN M3 in December 2025, it became the first transcatheter mitral valve replacement system delivered by a fully percutaneous transseptal approach, TCTMD reported, and it is indicated for symptomatic moderate-to-severe mitral regurgitation or mitral valve dysfunction with mitral annular calcification in patients a heart team judges unsuitable for surgery or transcatheter edge-to-edge repair.
For a device used in patients with no good surgical rescue, the useful question is not only whether a lot is on the list. It is whether your team can show it checked.
What Edwards and the FDA ask users to do
On Oct. 5, Edwards sent affected customers a letter recommending that they share the notice with clinical staff, search inventory and remove affected product, and work with their Edwards representative to return it. The FDA says not to use the affected lots. U.S. customers with questions or adverse reactions can contact Edwards at 1-800-424-3278, and clinicians can report problems to MedWatch, the FDA's adverse event reporting program.
What we do not know
The alert does not give the number of units distributed, the number of procedures performed with the affected lots or a root cause, and it does not say whether the SAPIEN M3 valve itself is implicated. We did not see the Edwards customer letter, and we found no other public report on this alert beyond the FDA page.
What it means in clinic
Most physicians will never handle this device. Referring cardiologists may be asked by patients whether a scheduled procedure is affected; the accurate answer is that four lots are named and that the implanting program, not the referring office, holds the lot numbers.
If you direct or work in a structural heart program, confirm that someone has checked inventory against the four lot numbers, documented the check with a date and filed any events with MedWatch. Add the FDA early alert page to the sources your device-safety coordinator reviews each week.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
